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DOT-ELISA FOR THE DIAGNOSIS OF NEUROCYSTICERCOSIS
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SUMMARY
The aim of the present study was to standardize and evaluate dot-Enzyme linked immunosorbent assay (Dot-ELISA), a simple
and rapid test for the detection of cysticercus antibodies in the serum for the diagnosis of neurocysticercosis (NCC). The antigen used
in the study was a complete homogenate of Cysticercus cellulosae cysts obtained from infected pigs and dotted on to nitrocellulose
membrane. Test sera were collected from the patients of NCC, and control sera from patients with other diseases and healthy students
and blood donors of the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Hospital, Pondicherry,
during a study period from 2001 to 2003. Dot-ELISA detected antibodies in 14 of 25 (56%) in clinically suspected cases of NCC, 13
of 23 (56.5%) in CT/MRI proven cases of NCC and 2 of 25 (8%) each in non-cysticercal CNS infection controls and healthy controls.
The test showed a sensitivity of 56.25%, specificity of 92%, positive predictive value of 87.09%, and negative predictive value of
70.76%. Results of the present study shows that the Dot-ELISA as a simple test can be used in the field or poorly equipped laboratories
for diagnosis of NCC .
KEYWORDS: Neurocysticercosis; ELISA; Dot-ELISA; Cysticercus antigen.
INTRODUCTION
Neurocysticercosis (NCC) is an important parasitic disease of the
human nervous system and constitutes a public health problem for most
of the developing world23. It has been estimated that the NCC infects
approximately 50 million people world-wide and cause at least 50,000
deaths annually2. The NCC is endemic in many parts of the world.
Taeniasis/cysticercosis is of economic importance in several countries
and regions, such as Mexico, Central and South America (except Uruguay
and Argentina), Africa, India, Indonesia, Thailand and China10,27. In recent
years, an increased incidence of NCC is being reported from America
owing to an increase in immigration from endemic regions and also due
to improved ease of diagnosis with the imaging techniques. It is common
among Hispanic immigrants to the American South west4,26,28,31.
NCC is difficult to diagnose clinically because of its varied clinical
presentation and non-specificity. Recently, immunological tests are being
increasingly used in adjunct with imaging techniques to aid the diagnosis
of NCC. Several immunological tests for demonstration of specific
antibodies in the serum and cerebrospinal fluid (CSF) have been devised
over the years. The first serological reaction for cysticercosis in the CSF
was described by MOSES in the year 191118. In most laboratories, indirect
haemagglutination (IHA)12, enzyme-linked immunosorbent assay
(ELISA)25, radioimmunoassay (RIA)16 and most recently the Western
blot test34 are being used.
However, the test such as Western blot or plate ELISA although are
specific and sensitive, have the disadvantages of being the tests that
require expensive equipment, technical expertise, hence difficult to adapt
in the field or in the not-so well equipped laboratories. Several authors
have hence used dot-enzyme linked immunosorbent assay (Dot-ELISA),
a simplified ELISA technique for detection of specific cysticercus
antibodies in serum and CSF samples9,36,37. The aim of the present study
was to standardize and evaluate dot-Enzyme linked immunosorbent assay
(Dot-ELISA), a simple and rapid test for the detection of cysticercus
antibodies in the serum for the diagnosis of neurocysticercosis in the
less equipped laboratories or in the field situation.
MATERIALS AND METHODS
Patients and controls: Test sera were collected from the patients of
neurocysticercosis (NCC), and control sera from patients with other
diseases and healthy students and blood donors of the Jawaharlal Institute
of Postgraduate Medical Education and Research (JIPMER) Hospital,
Pondicherry, during a study period from 2001 to 2003.
The groups included:
Group 1 (strong clinical suspects of NCC): This group included 25
patients with single contrast enhancing ring lesions/single calcified
nodular lesion of less than 0.5 cm diameter on CT Scan/MRI presenting
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with seizures, hydrocephalus or intracranial hypertension or psychiatric
disturbances. This group comprises clinically strongly suspected cases
of NCC, a well studied and well accepted clinical entity.
Group 2 (CT/MRI proven cases of NCC): This group included 23
patients with either CT Scan/MRI proven multiple contrast enhancing
ring lesions of less than 0.5 cm diameter or multiple nodular calcified
lesions of less than 0.5 cm diameter with or without meningoencephalitis.
This group comprised clinico-radiologically definite cases of NCC.
Group 3 (Non-cysticercal CNS infection control): This group
included 25 patients presenting with single/multiple margin enhancing
lesions/calcified polymorphic lesions of more than 0.5 cm diameter with
or without meningoencephalitis or microbiologically proven cases of
tubercular or cryptococcal meningitis. This group comprised non-
cysticercus chronic meningoencephalitis and thus formed an important
control group of other infectious diseases.
Group 4 (Healthy controls): This group included 25 healthy adults
(blood donors and students) who had not suffered from cysticercosis or
any other disease during the study period from 2001 to 2003.
The informed consent was obtained from all human adult participants
and from parents or legal guardians of minors. The project was approved
by the JIPMER research council.
Serum: Serum samples were collected from all the patients and
controls described earlier. Five milliliters of venous blood was also
collected from each patient under aseptic precautions and was allowed
to clot. The serum was separated and preserved with 0.05 mol/L sodium
azide and stored at -20 °C until used.
Preparation of cysticercus antigen: Preparation of C. cellulosae
porcine complete homogenate antigen was carried out according to the
method described by SREENIVASAMURTHY et al.32. In this procedure,
approximately 100 cysts that were dissected free from pork tissue were
washed thrice in PBS (pH 7.2) to remove extraneous matter. The cysts
were homogenized in a glass tissue homogenizer with PBS (pH 7.2)
containing 0.1 mM phenyl methyl sulphonyl fluoride (PMSF).
Homogenization was done under cooling condition. The homogenized
tissue suspension was then sonicated eight times at 12 KHz with 30
seconds cooling interval. Each cycle of sonication was for one minute
and it was done again under cooling condition in an ice bath. The
sonicated material was centrifuged at 40 °C for 30 minutes at 14,000
rpm. The supernatant was collected as the complete homogenate antigen,
aliquoted to 1 ml cryoprotected vials and stored at -20 °C.
Detection of cysticercus antibodies in the serum: The circulating
cysticercus antibodies were detected in the serum by a plate ELISA and
Dot-ELISA.
Plate-enzyme linked immunosorbent assay (ELISA): The presence
of cysticercus antibodies in the patient’s serum was also detected by a
commercially available plate ELISA kit marketed with the brand name
UBI, MAGIWEL enzyme immunoassay-cysticercosis (Germany). The
tests were carried out according to manufacturer’s instructions. Result
was noted as per the instructions provided along with the kit.
Dot-enzyme linked immunosorbent assay (Dot - ELISA): The Dot-
ELISA depends upon the principle that when test serum is layered on
the nitrocellulose membrane bound with the cysticercus antigen, the
specific cysticercus antibodies, if present in the serum, will bind to the
cysticercus antigen dot. This binding reaction is detected visually by
addition of an enzyme-labeled second antibody and subsequent
development of the label antibody.
Dot-ELISA was standardized to detect cysticercus antibodies in the
serum of NCC patients.
The procedure consists of the following steps:
(i) 2 µl of complete homogenate (CH) porcine cysticercus antigen
of 0.72 g% was added to square sized nitrocellulose membrane pasted
on plastic strips (3 cm × 0.5 cm). The strips with the antigen were air
dried for 30 minutes to 45 minutes. The antigen in the strips was then
blocked with a diluent (2% BSA in PBS, pH 7.2) for three hours over a
shaker. Washing of the strips was done three times with 0.1% Tween 20
in PBS (pH 7.2) over a period of 15 minutes.
(ii) The strips were incubated at room temperature with 2 µl of patients
serum diluted with 20 µl of 0.1% Tween 20 in PBS (pH 7.2), for 90
minutes with continuous shaking.
(iii) Washing of the strips was then repeated three times. Then
commercially available rabbit antihuman IgG peroxidase conjugate
marketed by BANGALORE GENEI, INDIA was added as (1:1000
dilutions in PBS Tween 20) and incubated for 30 minutes over the shaker.
Again washing was repeated three times.
(iv) Then 5 mg of diaminobenzidine substrate in 5 ml of PBS Tween
20 (1:1000 dilutions) was added to the strips followed by 5 µl of
hydrogen peroxide. The strips were then incubated for 10 minutes in the
dark.
(v) Reaction was stopped with distilled water and the results were
read immediately. The results were read as development of a deep reddish
brown coloured dot in nitrocellulose membrane was considered as
reactive, where as colourless dot was considered as non-reactive.
Statistical analysis of the immunoassays: The statistical analysis
was carried out using Epi Info package supplied by the WHO.
The serum samples were tested in a single blind manner. The sources
of the specimen (whether they were from the patients or from control
subjects) were not known to those performing the different tests with
these specimens. The sensitivity, specificity, positive predictive valve,
and negative predictive valve of the tests were calculated according to
the method described by GALEN & GAMBINO6.
RESULTS
Dot-ELISA: The serum samples, which showed development of
brick red coloured dot on nitrocellulose membrane, were considered
reactive. The cysticercus antibodies could be demonstrated by Dot-ELISA
in the sera of different groups of NCC and controls. Dot-ELISA detected
antibodies in 14 of 25 (56%) in clinically suspected cases of NCC, 13 of
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23 (56.5%) in CT/MRI proven cases of NCC and 2 of 25 (8%) each in
non-cysticercal CNS infection controls and healthy controls.
The sensitivity, specificity, positive predictive value and negative
predictive value of the tests by Dot-ELISA were found to be 56.25%,
92%, 87.09% and 68.66% respectively.
Plate ELISA: Commercial microtitre plate ELISA demonstrated a
positivity of 9 of 25 (36%) in clinically suspected cases of NCC, 12 of
23 (52.1%) in CT/MRI proven cases of NCC and 1 of 25 (4%) in healthy
controls. However, no antibodies were detected in serum of non-
cysticercal CNS infection controls.
The sensitivity, specificity, positive predictive value and negative
predictive value of the tests by Plate ELISA were found to be 43.75%,
98%, 95.45% and 64.4% respectively.
DISCUSSION
In India, the NCC has been reported widely from different parts of
the country as Delhi1, Uttaranchal region35, Chandigarh14,
Pondicherry33,38. Before the advent of CT/MR era, the frequency of NCC
as a cause of epilepsy in India was reported to vary from 2.2% to 9.6%11,15.
After the availability of CT/MR imaging, NCC has been found to be the
cause in 9% to 18.6% of patients with epilepsy7,8. Varied reports are
available regarding the role of NCC in intracranial space occupying
lesion. While some workers report that 1% of intracranial space-
occupying lesions in children in India are accounted for by parasites22,
others show that 17.4% - 29.2% of cases of intracranial space occupying
lesions and epilepsy are due to cysticercosis10. In Bangalore,
approximately 26% of the space-occupying sessions of the CNS were
found to be caused by cysticercosis13. In JIPMER, Pondicherry a total of
21 childhood neurocysticercosis was reported over five years from 1984
to 198933.
Demonstration of specific antibodies in the serum is the most common
approach for the diagnosis of parasitic diseases. A number of serological
tests have been evaluated and used for the detection of specific antibodies
in the serum with variable results in the diagnosis of NCC.
The ELISA and EITB are the most frequently used antibody-based
tests for the detection of antibodies in the serum5. ELISA and EITB were
used to detect serum IgG antibodies to Taenia solium metacestodes17,29
while ELISA also measured IgM antibodies against Cysticercus antigen
in both serum and CSF samples of patients with active NCC25. The ELISA
has been used widely by various authors for the detection of cysticercus
antibodies in the serum with variable sensitivities of 50%25, 10.4%17, 79%3
and 93%30 and specificities of 70%25 and 93%30 for the diagnosis of NCC.
Also the ELISA test demonstrated cross reactions with other parasitic
diseases as hydatid disease, schistosomiasis and angiostrongyliasis3,17. In
the present study, the plate ELISA showed a low sensitivity of 43.75% but
a high specificity of 98%.
Dot-ELISA, developed as a modification of the ELISA using
nitrocellulose membrane as a carrier of protein, has become increasingly
popular as a field test for the diagnosis of many parasitic diseases such
as visceral leishmaniasis19,20, malaria, schistosomiasis mansoni and
fascioliasis21 and cystic echinococcosis24.
Dot-ELISA has also been employed in NCC for the detection of
cysticercus antibodies in the serum as well as in the CSF9,36,37. A
preliminary study conducted on CSF samples for the presence of specific
cysticercus antibodies, with the cysticercus antigen dotted on a new solid
phase of synthetic polyester fabric impregnated with a polymerized resin,
revealed, 14 out of 15 CSF samples of NCC to have titres ranging from
one to 12836. Another study on CSF samples for cysticercus antibody
detection, by Dot-ELISA showed sensitivity and specificity of 95.1%
and 90.6% respectively for C. cellulosae antigen, while showed a
sensitivity of 97.6% for Cysticercus longicollis antigen and specificities
of 96.9% for the membrane – C. longicollis (M-Cl) antigen and 100%
for the vesicular fluid – C. longicollis (VF-Cl) antigen37. For testing
serum samples for specific cysticercus antibodies in patients with NCC,
Dot-immunogold-silver staining (Dot-IGSS) and Dot-ELISA using T.
solium antigen have been compared. The average titre of the sera detected
by Dot-IGSS was 1:27,470, which was significantly higher than that
detected by Dot-ELISA9. In the present study, Dot-ELISA using the
complete homogenate antigen of T. solium, tested only on serum samples
for specific cysticercus antibodies was found to be only 56.25% sensitive
and 92% specific for diagnosis of NCC. Although the test is of moderate
sensitivity, it has potential for wider use for diagnosis of NCC, specially
in the field or in poorly equipped laboratories in the absence of imaging
facilities such as CT and MR which are highly expensive.
Dot-ELISA as a test for use in the field or poorly equipped
laboratories for the diagnosis of NCC offers many advantages. The
foremost advantage is that the test is a rapid test, is easy to perform and
the results are read visually, eliminating the need for an ELISA reader.
Second, the test can be carried out by imparting minimal basic training
to locally available technical staff and, it is easy to use. Third,
nitrocellulose binds more antigens than microtitre plates. Finally the
test is inexpensive because the cost of nitrocellulose membrane is less
than that of microtitre plates.
RESUMO
Dot-ELISA no diagnóstico da neurocisticercose
O objetivo do presente estudo foi estandardizar e avaliar o Dot-
ELISA, um teste simples e rápido para detectar anticorpos de cisticercos
no soro para diagnóstico da neurocisticercose (NCC). O antígeno usado
no estudo foi um homogenizado completo de cistos de Cysticercus
cellulosae obtidos de porcos infectados e marcados sobre a membrana
de nitrocelulose. Os soros testados foram coletados de pacientes com
NCC e os soros controle de pacientes com outras doenças e estudantes
saudáveis e doadores e sangue do “Jawaharlal Institute of Postgraduate
Medical Education and Research Hospital”, em Pondicherry, durante o
período de estudo de 2001 a 2003. Dot-Elisa detectou anticorpos em 14
de 25 (56%) casos suspeitos de NCC, em 13 de 23 (56,5%) em CT/MRI
casos provados de NCC e em 2 de 25 (8%) cada em controles de infecções
do sistema nervoso não devidas à cisticercose e controles saudáveis. O
teste mostrou sensibilidade de 56,25%, especificidade de 92%, valor
preditivo positivo de 87,09% e valor preditivo negativo de 70,76%.
Resultados do presente estudo mostram que o Dot-ELISA como teste
simples pode ser usado em trabalhos de campo ou em laboratórios
pobremente equipados para o diagnóstico da NCC.
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